Zymeworks Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
ZYME$30.81+4.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(Expressed in thousands of U.S. dollars except share data)
| September 30,2025 | December 31,2024 | |
|---|---|---|
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $64,834 | $66,103 |
| Short-term marketable securities (note 5) | 187,099 | 159,673 |
| Accounts receivable | 29,352 | 55,815 |
| Prepaid expenses and other current assets | 10,427 | 18,860 |
| Total current assets | 291,712 | 300,451 |
| Long-term marketable securities (note 5) | 47,427 | 98,428 |
| Long-term prepaids and other assets | 7,388 | 8,919 |
| Deferred tax asset | 4,862 | 4,385 |
| Property and equipment, net | 15,819 | 17,650 |
| Operating lease right-of-use assets | 16,648 | 16,666 |
| Intangible assets, net | 1,397 | 4,576 |
| Goodwill (note 6) | 12,016 | 12,016 |
| Total assets | $397,269 | $463,091 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (note 7) | $34,430 | $59,838 |
| Income tax payable | 1,016 | 128 |
| Current portion of operating lease liability (note 11) | 3,400 | 2,740 |
| Deferred revenue (note 9) | 3,197 | 25,588 |
| Total current liabilities | 42,043 | 88,294 |
| Long-term portion of operating lease liability (note 11) | 15,504 | 15,738 |
| Deferred revenue (note 9) | 14,607 | 14,607 |
| Other long-term liabilities (note 7) | 278 | 923 |
| Deferred tax liability | 4,773 | 4,761 |
| Total liabilities | 77,205 | 124,323 |
| Stockholders’ equity: | ||
| Common stock, $0.00001 par value; 900,000,000 authorized shares at September 30, 2025 and December 31, 2024, respectively; 75,139,281 and 68,964,319 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively (note 8a) | 1,092,929 | 1,015,618 |
| Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of September 30, 2025 and December 31, 2024 (note 8a) | — | — |
| Exchangeable shares, no par value, 569,189 and 570,637 issued and outstanding shares at September 30, 2025 and December 31, 2024, respectively (note 8a) | 8,168 | 8,188 |
| Additional paid-in capital | 111,489 | 152,249 |
| Accumulated other comprehensive loss | (6,050) | (6,952) |
| Accumulated deficit | (886,472) | (830,335) |
| Total stockholders’ equity | 320,064 | 338,768 |
| Total liabilities and stockholders’ equity | $397,269 | $463,091 |
| Related party transactions (note 8c) | ||
| Research collaboration and licensing agreements (note 9) | ||
| Commitments and contingencies (note 13) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.